<DOC>
	<DOCNO>NCT00267267</DOCNO>
	<brief_summary>The Torcetrapib project terminate December 2 , 2006 due safety finding . Cholesterol level measure six week subject treat two different kind combination cholesterol medication see different treatment compare one another .</brief_summary>
	<brief_title>A Clinical Trial Comparing Torcetrapib/Atorvastatin Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder .</brief_title>
	<detailed_description>For additional information please call : 1-800-718-1021</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Torcetrapib</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Specific LDLC level base CHD risk sixweek washout period . Women pregnant lactating , plan become pregnant . Subjects take drug know associate increase risk myositis combination HMGCoA reductase inhibitor . Subjects require systemic steroid Subjects medical condition laboratory abnormality could affect subject safety , preclude evaluation response , render unlikely subject would complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
</DOC>